We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.
Greg Madison is a seasoned executive who brings strong operating experience and a track record of success leading small to medium size organisations. Prior to joining Shield, he was Chief Executive Officer at Melt Pharmaceuticals in Boston, MA, a company developing a sublingual formulation of midazolam and ketamine, providing needle and opioid-free procedural sedation and analgesia. Prior to Melt Pharmaceuticals, he was Chief Executive Officer of Keryx Biopharmaceuticals from 2015 to 2018, where he led the transformation of the organisation from development stage to commercial stage focused on Auryxia, an oral product for the treatment of hyperphosphatemia and iron deficiency anaemia, and ultimately leading to a merger with Akebia Therapeutics. In 2013 and 2014, he was Chief Commercial Officer at AMAG Pharmaceuticals where he was closely involved with Feraheme, a leading intravenous product for the treatment of iron deficiency. From 2000-2012, Greg was at Genzyme Corporation, ultimately serving as Vice President and General Manager of its Nephrology Division, where he led a division that had revenues in excess of $1 billion dollars, led by the world’s leading phosphate binder, Renvela. Greg began his career as a sales representative for Janssen Pharmaceuticals, a division of Johnson and Johnson.
Hans-Peter is Chief Financial Officer at Shield and brings extensive international experience to the senior team. Hans-Peter studied at the University of Zurich and Cleveland State University, Ohio, Hans-Peter is a US Certified Public Accountant (CPA). Hans-Peter began his career in 1991 in public practice with Deloitte in Cleveland, Ohio, before joining Ernst & Young (Switzerland) where he became a partner in 2001 and moved back to the Cleveland office in 2003 as an audit partner. In 2006 he joined Crowe Horwath (now Crowe) as an audit partner within the 8th largest global accounting network. In 2011 Hans-Peter left public practice to become Head of Group Accounting at COFRA Group, a privately held Swiss conglomerate with activities in retail, real estate and investment, employing over 50,000 people worldwide. In 2017, he was appointed as Chief Financial Officer at Vicarius Pharma, a start-up company offering research-driven pharma and biotech companies a platform to build a dedicated European commercial organisation to market and sell their assets through long-term license and partnership agreements.
Brian leads our US organisation and global commercial strategy. He brings to Shield over 30 years of highly relevant and successful experience of building high-performing teams and launching and commercialising around 30 pharmaceutical products in both Big Pharma and biotech companies. Over the last 11 years he has gained deep expertise in start-up and scaled growth stage companies and has supported the raising over $100 million. Most recently, he served as Executive Vice President and Chief Commercial Officer at Acasti Pharma. Prior to Acasti, he was the Executive Vice President and Chief Commercial Officer at Veru, Inc., a urology, oncology, and female health products company. He also served as Chief Commercial Officer for Telesta Therapeutics, where he led the development and implementation of the global commercial strategy for the first oncology product for bladder cancer in 25 years. Previously, he served as Vice President of Commercial Operations and Market Access for Horizon Therapeutics, as CEO and President of Exsto Therapeutics and Head of Market Access at Dendreon. He has held management roles with Novartis and Merck & Co. He earned his master’s degree in Marketing from Central Michigan University, as well as a B.S. in Physiology from Central Michigan University.
Tim has worked in the pharmaceuticals and biotech sectors since 1990 when he joined ICI Pharmaceuticals which evolved into AstraZeneca. In his 17 years with AstraZeneca he worked primarily in Finance roles supporting commercial operations, in particular as VP Finance in the International Sales and Marketing Organisation, but also spent two years in a commercial role. His last position in AstraZeneca was as Group Financial Controller. In 2007 Tim became CFO of Archimedes Pharma, a UK-based private equity backed specialty pharma company where he was Interim COO for a period, and then in 2012 joined Oxford BioMedica PLC, a UK-listed gene and cell therapy company, as CFO. Tim joined Shield as CFO in August 2018 and was appointed CEO in April 2020.
Lucy Huntington-Bailey has been the Group’s Legal Advisor since August 2015 and was an integral member of the team working towards the successful admission of Shield Therapeutics to the AIM market in early 2016. Having worked previously at a boutique corporate law firm and prior to that an international US law firm in Singapore, Lucy brings to Shield a wealth of experience in the oil and gas sector as well as the pharmaceutical industry. Lucy was promoted to Senior In-House Counsel in December 2016, General Counsel in 2018 and is responsible for the management of the Group’s legal team and all legal advice and services. Lucy was appointed by the Board of Directors to the role of Company Secretary in September 2017. Lucy is admitted as a Solicitor of the Senior Courts of England and Wales.
David joined Shield Therapeutics in 2011 as Director of Manufacturing with the primary objective of creating a robust manufacturing process with multiple CMOs for the development and commercialisation of our lead product, Feraccru®. During his tenure David has also had a central role in developing and managing the Company’s intellectual property, whilst more recently adding responsibility for the development of commercial alliances. Prior to joining Shield, David gained over 18 years’ of experience in chemical and pharmaceutical development at GlaxoSmithKline (GSK), where he led several successful projects and teams including the manufacturing elements of the successful Promacta® and Relovair® developments.
Jackie has over 20 years’ experience in regulatory affairs. She holds an MA in biochemistry from Lady Margaret Hall in Oxford, where she also obtained a doctorate in immunology and molecular biology. Following completion of her academic studies, Jackie spent a number of years working as a research scientist, including a period at Johns Hopkins School of Medicine in Baltimore, USA. Since moving into the pharmaceutical industry, Jackie has worked in regulatory affairs for large, medium and small pharmaceutical companies, including Boehringer Ingelheim, Abbott and Archimedes. She has been involved in a broad range of global, EU and national applications across many therapeutic areas and has led several major regulatory projects, including successful MAA and NDA submissions, including the NCEs Kaletra and Humira. Jackie has run the group’s regulatory activities since 2012.